baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

Applied Therapeutics/ US03828A1016 /

2024-04-25 9:59:55 PM	Chg. -0.04	Volume	Bid-	Ask-	High	Low
4.25USD	-0.82%	20,872 Turnover: 88,777.24	-Bid Size: -	-Ask Size: -	4.33	4.19

GlobeNewswire 04-15 Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer

GlobeNewswire 04-04 Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at AC...

GlobeNewswire 03-28 Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatmen...

GlobeNewswire 03-06 Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results

GlobeNewswire 02-28 Applied Therapeutics Announces $100 Million Private Placement

GlobeNewswire 02-28 Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govore...

GlobeNewswire 02-15 Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007...

GlobeNewswire 01-04 Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic...

GlobeNewswire 01-03 Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatmen...

GlobeNewswire 2023-11-09 Applied Therapeutics Reports Third Quarter 2023 Financial Results

GlobeNewswire 2023-11-02 Applied Therapeutics to Present at the UBS Biopharma Conference 2023

GlobeNewswire 2023-11-01 Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesda...

GlobeNewswire 2023-09-28 Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2...

GlobeNewswire 2023-09-06 Applied Therapeutics Announces Successful Pre-NDA Meeting with the FDA and Confirms Plans to Submit ...

GlobeNewswire 2022-03-26 Bragar Eagel & Squire, P.C. Is Investigating Corcept, Verra, Core Scientific, and Applied Therapeuti...

GlobeNewswire 2022-03-21 Bragar Eagel & Squire, P.C. Is Investigating Core Scientific, Applied Therapeutics, and Lilium and E...

GlobeNewswire 2022-03-15 Bragar Eagel & Squire, P.C. Is Investigating Verra, Corcept, Core Scientific, and Applied Therapeuti...

GlobeNewswire 2022-03-10 Applied Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results

GlobeNewswire 2022-03-10 Bragar Eagel & Squire, P.C. Is Investigating Verra and Applied Therapeutics and Encourages Investors...

GlobeNewswire 2022-03-05 Bragar Eagel & Squire, P.C. Is Investigating Cronos, Applied Therapeutics, Everbridge, and Agrify an...

GlobeNewswire 2022-03-01 Applied Therapeutics to Present at the Cowen and Barclays Investor Conferences

GlobeNewswire 2022-02-28 Applied Therapeutics Supports 15th Annual Rare Disease Day

GlobeNewswire 2022-02-12 Bragar Eagel & Squire, P.C. Is Investigating Applied Therapeutics, Gatos, Anavex, and Greenidge and ...

GlobeNewswire 2022-02-10 Applied Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire 2022-02-01 Bragar Eagel & Squire, P.C. Is Investigating Embark, Affirm, Applied Therapeutics, and Gatos and Enc...

Applied Therapeutics/ US03828A1016 /

If you wish to receive reply to your feedback, please provide your email address.